BRCA1 and cancer: Genetically engineered mice carrying Brca1 and Tp53 mutations showed hyperproliferation and malignancy in their mammary glands at 4 months of age; the inactivation of the RANKL/RANK pathway in these mice largely prevented the occurrence of malignant tumors and resulted in significantly prolonged survival.